Camurus AB (publ) (CAMX.ST)
SEK 537.5
(3.37%)
SEK 537.5
(3.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 562.54 Million SEK | 577.63% |
| 2022 | 87.58 Million SEK | 182.51% |
| 2021 | -97.72 Million SEK | 49.49% |
| 2020 | -196.58 Million SEK | 44.87% |
| 2019 | -353.04 Million SEK | -24.19% |
| 2018 | -284.7 Million SEK | -18.11% |
| 2017 | -239.28 Million SEK | -142.09% |
| 2016 | -98.83 Million SEK | 50.72% |
| 2015 | -200.71 Million SEK | -412.68% |
| 2014 | 61.32 Million SEK | -49.97% |
| 2013 | 122.78 Million SEK | 558.97% |
| 2012 | 18.55 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 100.83 Million SEK | 832.3% |
| 2024 Q2 | 88.59 Million SEK | -12.14% |
| 2023 Q3 | 113.63 Million SEK | -70.43% |
| 2023 Q1 | 80.44 Million SEK | 224.77% |
| 2023 FY | - SEK | 577.63% |
| 2023 Q4 | -12.84 Million SEK | -111.3% |
| 2023 Q2 | 384.31 Million SEK | 377.75% |
| 2022 Q4 | 24.76 Million SEK | -44.65% |
| 2022 Q1 | 7.97 Million SEK | 153.71% |
| 2022 Q2 | 10.09 Million SEK | 26.66% |
| 2022 Q3 | 44.75 Million SEK | 343.32% |
| 2022 FY | - SEK | 182.51% |
| 2021 Q4 | -14.83 Million SEK | -415.24% |
| 2021 Q2 | -56.7 Million SEK | -143.41% |
| 2021 Q1 | -23.29 Million SEK | 70.31% |
| 2021 FY | - SEK | 49.49% |
| 2021 Q3 | -2.88 Million SEK | 94.92% |
| 2020 Q3 | -19.94 Million SEK | 3.59% |
| 2020 Q4 | -78.46 Million SEK | -293.48% |
| 2020 FY | - SEK | 44.87% |
| 2020 Q1 | -74.4 Million SEK | 13.41% |
| 2020 Q2 | -20.68 Million SEK | 72.2% |
| 2019 Q1 | -82.25 Million SEK | 19.34% |
| 2019 Q3 | -75.16 Million SEK | 30.16% |
| 2019 FY | - SEK | -24.19% |
| 2019 Q2 | -107.62 Million SEK | -30.85% |
| 2019 Q4 | -85.92 Million SEK | -14.33% |
| 2018 Q4 | -101.96 Million SEK | -84.58% |
| 2018 FY | - SEK | -18.11% |
| 2018 Q3 | -55.24 Million SEK | 30.98% |
| 2018 Q2 | -80.04 Million SEK | -76.53% |
| 2018 Q1 | -45.34 Million SEK | 30.24% |
| 2017 FY | - SEK | -142.09% |
| 2017 Q4 | -64.99 Million SEK | 1.52% |
| 2017 Q3 | -65.99 Million SEK | -14.38% |
| 2017 Q2 | -57.69 Million SEK | -14.08% |
| 2017 Q1 | -50.57 Million SEK | -47.86% |
| 2016 Q2 | -25.03 Million SEK | -4.22% |
| 2016 Q3 | -15.58 Million SEK | 37.74% |
| 2016 Q4 | -34.2 Million SEK | -119.5% |
| 2016 FY | - SEK | 50.72% |
| 2016 Q1 | -24.01 Million SEK | 39.12% |
| 2015 Q1 | 13.95 Million SEK | -85.63% |
| 2015 Q2 | -146.79 Million SEK | -1151.89% |
| 2015 Q3 | -28.26 Million SEK | 80.75% |
| 2015 Q4 | -39.45 Million SEK | -39.59% |
| 2015 FY | - SEK | -412.68% |
| 2014 FY | - SEK | -49.97% |
| 2014 Q4 | 97.12 Million SEK | 6170.0% |
| 2014 Q3 | -1.6 Million SEK | 0.0% |
| 2013 FY | - SEK | 558.97% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | 1381.803% |
| Amniotics AB (publ) | -27.14 Million SEK | 2172.523% |
| BioArctic AB (publ) | 275.38 Million SEK | -104.274% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 252.947% |
| Cantargia AB (publ) | -284.31 Million SEK | 297.86% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 2973.206% |
| CombiGene AB (publ) | -35.33 Million SEK | 1691.986% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 499.39% |
| Genovis AB (publ.) | 64.57 Million SEK | -771.19% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 589.565% |
| Mendus AB (publ) | -97.84 Million SEK | 674.929% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 1619.406% |
| Intervacc AB (publ) | -68.98 Million SEK | 915.519% |
| Kancera AB (publ) | -61.88 Million SEK | 1008.958% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 2200.381% |
| LIDDS AB (publ) | -39.67 Million SEK | 1518.062% |
| Lipum AB (publ) | -37.11 Million SEK | 1615.518% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 4747.596% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | -1691.316% |
| NextCell Pharma AB | -40.98 Million SEK | 1472.558% |
| OncoZenge AB (publ) | 7.26 Million SEK | -7642.155% |
| Saniona AB (publ) | -69.69 Million SEK | 907.153% |
| Simris Alg AB (publ) | -22.36 Million SEK | 2615.517% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 277.199% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 299.461% |
| Xintela AB (publ) | -53.47 Million SEK | 1152.056% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 431.269% |
| Ziccum AB (publ) | -20.34 Million SEK | 2865.436% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 4056.847% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 3392.719% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -28127150.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 336.747% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 27145.433% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 4288.407% |
| Corline Biomedical AB | -1.69 Million SEK | 33367.002% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 424.563% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 1126.43% |
| Aptahem AB (publ) | -10 Million SEK | 5720.264% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | -4770.941% |
| Fluicell AB (publ) | -25.91 Million SEK | 2270.815% |
| Biovica International AB (publ) | -119.5 Million SEK | 570.725% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 1432.287% |
| AcouSort AB (publ) | -16.7 Million SEK | 3467.928% |
| Abliva AB (publ) | -93.6 Million SEK | 700.958% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 276.291% |
| 2cureX AB (publ) | -35.13 Million SEK | 1701.05% |
| I-Tech AB | 30.34 Million SEK | -1753.831% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 178.727% |
| Cyxone AB (publ) | -20.41 Million SEK | 2855.682% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 649.076% |
| Biosergen AB | 228 Thousand SEK | -246630.263% |
| Nanologica AB (publ) | -62.11 Million SEK | 1005.592% |
| SynAct Pharma AB | -222.7 Million SEK | 352.601% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 1382.563% |
| BioInvent International AB (publ) | -312.7 Million SEK | 279.895% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | -181710.396% |
| Alzinova AB (publ) | 41.99 Thousand SEK | -1339324.748% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 342.872% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 6483.505% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 618.198% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 5004.918% |